Biotechnology : alternatives to human plasma-derived therapeutic proteinsLYNCH, Thomas J.Baillière's best practice & research. Clinical haematology. 2000, Vol 13, Num 4, pp 669-688, issn 1521-6926Article

Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non-small cell lung cancerLYNCH, Thomas J.Seminars in oncology. 2001, Vol 28, Num 3, pp 5-9, issn 0093-7754, SUP9Conference Paper

Novel agents in the treatment of lung cancerLYNCH, Thomas J; JÄNNE, Pasi A; GURUBHAGAVATULA, Sarada et al.Clinical cancer research. 2004, Vol 10, Num 12, issn 1078-0432, 92 p., 2Conference Proceedings

Cetuximab in advanced non-small cell lung cancerGOVINDAN, Ramaswamy.Clinical cancer research. 2004, Vol 10, Num 12, pp 4241s-4244s, issn 1078-0432, 2Conference Paper

Novel agents in the treatment of lung cancer: proceedings of the fourth Cambridge ConferenceLYNCH, Thomas J; GURUBHAGAVATULA, Sarada; JACKMAN, David et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 79 p., 2Conference Proceedings

The role of gefitinib in lung cancer treatmentGIACCONE, Giuseppe.Clinical cancer research. 2004, Vol 10, Num 12, pp 4233s-4237s, issn 1078-0432, 2Conference Paper

The Phase III trial in the era of targeted therapy: Unraveling the go or no go decisionROBERTS, Thomas G; LYNCH, Thomas J; CHABNER, Bruce A et al.Journal of clinical oncology. 2003, Vol 21, Num 19, pp 3683-3695, issn 0732-183X, 13 p.Article

Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Non-Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative CareTEMEL, Jennifer S; GREER, Joseph A; ADMANE, Sonal et al.Journal of clinical oncology. 2011, Vol 29, Num 17, pp 2319-2326, issn 0732-183X, 8 p.Article

Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung CancerTEMEL, Jennifer S; GREER, Joseph A; ANDREW BILLINGS, J et al.The New England journal of medicine. 2010, Vol 363, Num 8, pp 733-742, issn 0028-4793, 10 p.Article

VEGF Polymorphisms and Survival in Early-Stage Non-Small-Cell Lung CancerSUK HEIST, Rebecca; RIHONG ZHAI; GEOFFREY LIU et al.Journal of clinical oncology. 2008, Vol 26, Num 6, pp 856-862, issn 0732-183X, 7 p.Article

Incorporating bortezomib into the treatment of lung cancer. DiscussionDAVIES, Angela M; LARA, Primo N; MACK, Philip C et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4647s-4651s, 2Conference Paper

Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. DiscussionBONOMI, Philip D; BUCKINGHAM, Lela; SEQUIST, Lecia et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4606s-4612s, 2Conference Paper

Genomic approaches to lung cancerTHOMAS, Roman K; WEIR, Barbara; MEYERSON, Matthew et al.Clinical cancer research. 2006, Vol 12, Num 14, issn 1078-0432, 4384s-4391s, 2Conference Paper

Oncogenic shock : Explaining oncogene addiction through differential signal attenuationSHARMA, Sreenath V; FISCHBACH, Michael A; HABER, Daniel A et al.Clinical cancer research. 2006, Vol 12, Num 14, issn 1078-0432, 4392s-4395s, 2Conference Paper

Mouse models of lung cancerDUTT, Amit; WONG, Kwok-Kin.Clinical cancer research. 2006, Vol 12, Num 14, issn 1078-0432, 4396s-4402s, 2Conference Paper

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non - small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitorsJÄNNE, Pasi A; JOHNSON, Bruce E.Clinical cancer research. 2006, Vol 12, Num 14, issn 1078-0432, 4416s-4420s, 2Conference Paper

Novel combinations based on epidermal growth factor receptor inhibitionADJEI, Alex A.Clinical cancer research. 2006, Vol 12, Num 14, issn 1078-0432, 4446s-4450s, 2Conference Paper

The evolving role of cetuximab in non-small cell lung cancerLILENBAUM, Rogerio C.Clinical cancer research. 2006, Vol 12, Num 14, issn 1078-0432, 4432s-4435s, 2Conference Paper

XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapyGURUBHAGAVATULA, Sarada; LIU, Geoffrey; PARK, Sohee et al.Journal of clinical oncology. 2004, Vol 22, Num 13, pp 2594-2601, issn 0732-183X, 8 p.Article

Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridolSHAPIRO, Geoffrey I.Clinical cancer research. 2004, Vol 10, Num 12, pp 4270s-4275s, issn 1078-0432, 2Conference Paper

Clinical trial design issues in the era of targeted therapiesSCHILLER, Joan H.Clinical cancer research. 2004, Vol 10, Num 12, pp 4281s-4282s, issn 1078-0432, 2Conference Paper

No association between the p21 codon 31 Serine-Arginine polymorphism and lung cancer riskLI SU; LIU, Geoffrey; WEI ZHOU et al.Cancer epidemiology, biomarkers & prevention. 2003, Vol 12, Num 2, pp 174-175, issn 1055-9965, 2 p.Article

Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer riskWEI ZHOU; LIU, Geoffrey; MILLER, David P et al.Cancer epidemiology, biomarkers & prevention. 2003, Vol 12, Num 4, pp 359-365, issn 1055-9965, 7 p.Article

Radiation dose escalation in limited-stage small-cell lung cancerROOF, Kevin S; FIDIAS, Panos; LYNCH, Thomas J et al.International journal of radiation oncology, biology, physics. 2003, Vol 57, Num 3, pp 701-708, issn 0360-3016, 8 p.Article

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non―Small-Cell Lung CancerSEQUIST, Lecia V; BESSE, Benjamin; ANANTHAKRISHNAN, Revathi et al.Journal of clinical oncology. 2010, Vol 28, Num 18, pp 3076-3083, issn 0732-183X, 8 p.Article